NCT00480571View on ClinicalTrials.gov

Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

BL-1020

BL-1020 Low Dose

DRUG

BL 1020 High Dose

BL 1020 High Dose

Trial Locations (2)

Unknown

Dept. of Psychiatry, Sheba Medical Center, Tel Litwinsky

010811

"Spitalul Clinic de Urgenţǎ Militar Central Dr Carol Davila,", Bucharest

Sponsors

Lead Sponsor

BioLineRx, Ltd.
All Listed Sponsors
lead

BioLineRx, Ltd.

INDUSTRY

NCT00480571 - Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder | Biotech Hunter | Biotech Hunter